By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


UCB Group 

Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: (32-2) 559-99-99 Fax: (32-2) 559-99-00


Company News
Merus Snags Three Cardiovascular Products from UCB Group (UCBJF.PK) in EUR 92 Million Deal 2/2/2016 6:08:49 AM
UCB Group (UCBJF.PK) Divests U.S. Generics Unit For $1.53 Billion 11/7/2014 5:53:40 AM
UCB Group (UCBJF.PK) Deploys IMS Health Nexxus Suite And Intelligent Cloud To Drive Commercial Productivity, Accelerate Time To Insight 10/22/2014 7:54:42 AM
New Indication For VIMPAT® (Lacosamide): UCB Group (UCBJF.PK)'s Anti-Epileptic Drug Approved By FDA As Monotherapy In The Treatment Of Patients With Partial-Onset Seizures 9/2/2014 11:37:51 AM
UCB Group (UCBJF.PK) And Dermira Enter Into Strategic Collaboration In Dermatology To Broaden Patient Access To Cimzia® (Certolizumab Pegol) 7/3/2014 6:38:35 AM
Beryllium Strengthens Collaboration With Key Partner, UCB Group (UCBJF.PK) 5/20/2014 10:17:06 AM
Biopharma Learns From Marvel, UCB Group (UCBJF.PK) And Massachusetts Institute of Technology (MIT) Begin Real Life Search For "X-Men" 4/30/2014 7:13:29 AM
UCB Group (UCBJF.PK) Not For Sale As Billionaire Shareholder Awaits Reward 12/2/2013 8:06:35 AM
Evotec AG (EVTG.F) Achieves First Milestones in Multi-Target Deal With UCB Group (UCBJF.PK) 10/28/2013 9:50:59 AM
UCB Group (UCBJF.PK)'s Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults With Active Ankylosing Spondylitis 10/18/2013 8:56:49 AM